VCBeat Health Contact Us
Home Pechoin Bio-Pharmaceuticals Officially Establishes Operations in Changping with Dual R&D Breakthroughs and Prepares for IPO

Pechoin Bio-Pharmaceuticals Officially Establishes Operations in Changping with Dual R&D Breakthroughs and Prepares for IPO

Dec 31, 2025 17:30 CST Updated 17:30
Unicet Biotech

Developer of γδ T Cell Therapeutics

InnoCare

Innovative Drug Developer

Berry Genomics

High-throughput Gene Sequencing Technology Developer

BeOne

Developer of Molecular Targeted and Immune Anti-Tumor Drugs


Image


Image

Insights into International Trends, Understanding Frontline Dynamics

Walking into Zhongguan Village Life Science Park Monthly

Let's take a look at what's new this month


Image
On December 24, the Beijing Changping Synthetic Biomanufacturing Transformation Acceleration Center, located in the Zhongguan Village Life Science Park, was brilliantly lit! A strategic signing ceremony that could reshape China's biomedical repair materials industry was grandly inaugurated here — The People's Government of Changping District, Beijing, and Shanghai Pechoin Biopharmaceuticals Co., Ltd. (the biopharmaceutical division under Pechoin) officially signed a strategic cooperation agreement, marking the official establishment of Pechoin's biopharmaceutical division in Changping!
In addition, to build a youth-friendly ecosystem in the Life Science Park and activate the Youth Talent Lounge, enriching the extracurricular life of young people in the park, Life Park Company plans to officially launch the "Youth Vitality Courses" within the park, relying on the Guli People Club. Click the link below for more details and registration!
Relevant Review
Park Headlines | Strength Certified! 10 Enterprises in Life Park Once Again Awarded as Beijing's "Specialized, Refined, Unique, and Innovative" SMEs
One Device in Hand, Financing Without Worry! "Beijing Rongxin Platform" WeChat Mini Program Officially Launched
@All Guli People! Youth Vitality Class is up to you, fill in the questionnaire to get rid of the work vibe!
Service Empowerment | Celebrate the Year-End Gathering, Enjoy the Annual Feast! Zhongguancun Life Science Park International Conference Center offers a one-stop "conference + catering + accommodation" solution to create a perfect closed loop!
Headlines of the Park | Settling in Changping! Pechoin Partners with Professional Research Institutions to Build Dual-Engine Laboratories and Research Platforms — China's Biomedical Independent Innovation Enters the "Changping Speed" Era
Image
In December, there was a constant stream of good news from the companies in the park.
In terms of winning awards,TopLead BioTechFounder Professor Yin Hang Honored with the 19th Outstanding Achievement Award in Pharmaceutical Development;Peking University International HospitalSuccessfully selected as a "2026 Medical Nutrition Weight Loss Teaching Unit";Jiahua MedicineAwarded the Second Prize in the Peking University HSBC-Cambridge Judge Global Innovation and Entrepreneurship Competition; The重量级 announcement of the shortlist for the 2025 Artificial Intelligence Medical Device Innovation Task "Challenge to Lead".Berry GenomicsSuccessfully selected with the intelligent ranking software for genetic disease risk loci jointly applied for with the Obstetrics and Gynecology Hospital affiliated to Tongji University.
In terms of product development,Qinghui Lianuo"Off-the-shelf" CAR-γδ T-cell therapy completes first dosing in Phase I clinical trial.InnoCareInnoCare's self-developed next-generation TRK inhibitor, Yinoxin® (Zolocitinib), has been approved for marketing. The Phase IIb study of Orelabrutinib for the treatment of SLE has met its primary endpoint and has been approved for a Phase III registrational clinical trial. The Phase II/III clinical trial of TYK2 inhibitor Soficitinib for the treatment of chronic spontaneous urticaria has been approved by the CDE.Berry GenomicsThe Launch of Third-Generation Genetic Sequencers Redefines the "Gold Standard" in Clinical Sequencing.BeOne MedicinesBeOne Medicines' self-developed pipeline drug BGB-B2033 receives FDA Fast Track designation for the treatment of hepatocellular carcinoma.Derived TideThe first innovative drug project independently developed —— YSC001 has successfully obtained the New Drug Clinical Trial (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration. Tongxin Biotech's four chemiluminescence IVD products have been certified, and the health check-up screening and chronic disease management product lines are continuously being improved.
In terms of the capital market,Derived TideSuccessfully completed a RMB hundreds of millions Series A financing round.MengMu BioAnnounced the completion of a Pre-A1 round of financing worth tens of millions of RMB in recent days.Yiming BioStrategic cooperation with Circurna to jointly promote the next generation of RNA therapies.
In addition, the Beijing Institute of Life Sciences/Tsinghua University Institute of Biomedical Interdisciplinary ResearchShao Feng LabIn《Nature》Published research titled "Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity." Following TLR and STING agonists, this study is the first to propose that activation of the cytosolic pattern recognition receptor ALPK1 can induce potent antitumor immune responses, demonstrating its potential application value as a novel target for immunotherapy.
Relevant Review
Company News | Zhibiao Biotech Completes First Subject Dosing in Phase II Clinical Trial for Oral Peptide GLP-1RA Weight Loss Study
Corporate News | Multiple Commercialized Products and New Indications from BeOne Medicines and InnoCare Included in China's 2025 National Reimbursement Drug List
Company News | Qinghui Lianuo's "Off-the-Shelf" CAR-γδ T Cell Therapy Completes First Dosing in Phase I Clinical Trial
Nature! Shao Feng's Lab Discovers Activation of Cytosolic Immune Receptor ALPK1 Triggers Anti-Tumor Immunity: A Novel Anti-Tumor Innate Immune Agonist Pathway Following TLR and STING
People's Daily Health Interview Focus: Berry Genomics' Third-Generation Gene Sequencer Launches, Redefining the "Gold Standard" in Clinical Sequencing
Enterprise News | Strong Entry into National-level List! Berry Genomics' AI + Medical Strength Recognized!
Corporate News | UMO Biotech Partners with Circurna to Advance Next-Generation RNA Therapies
Company News | Zhibio's Oral Peptide GLP-1RA Completes First Subject Dosing in Phase II Weight Loss Clinical Study
Company News | Global Top 8! Jiahua Medicine Sharp Wins Second Prize in Peking University HSBC-Cambridge Judge Global Innovation and Entrepreneurship Competition
Capital Market | Mengmou Bio Completes Tens of Millions in Pre-A1 Round Financing
Company News | Yanshengtide YSC001 Receives IND Approval Shortly After Raising Hundreds of Millions in Financing
Image
In December, Zhongguan Village Life Science Park carried out a series of industrial activities, including the publicity campaign for the construction of the technical market and the scientific and technological service talent echelon in Zhongguan Village Life Science Park, the online briefing on "Hong Kong Policy Empowerment and Acceleration of Scientific and Technological Innovation Overseas", etc., to comprehensively assist the high-quality development of enterprises.
Relevant Review
Event Announcement | Join Us for the宣讲 on the Construction of Technical Market and Science Service Talent Team in Beijing Zhongguan Village Life Science Park!
Dual-City Collaboration Empowers Overseas Expansion! Zhongguan Village Life Science Park Partners with Hong Kong-Shenzhen Innovation and Technology Park to Host Online Briefing, Decoding New Opportunities in Hong Kong's Support Policies

Note: The data is sourced from publicly available information. If there are any omissions, we appreciate your understanding.

Image